Pancreatic cancer is resistant to all current treatments.
Patients have extremely poor chances of surviving for five years after being diagnosed.
A new Tel Aviv University study finds that a small molecule has the ability to induce the self-destruction of pancreatic cancer cells.
The research was conducted with xenografts -- transplantations of human pancreatic cancer into immunocompromised mice.
The treatment reduced the number of cancer cells by 90% in the developed tumours a month after being administered.
The research holds great potential for the development of a new effective therapy to treat this aggressive cancer in humans.
The study was led by Prof. Malca Cohen-Armon and her team at TAU's Sackler Faculty of Medicine, in collaboration with Dr. Talia Golan's team at the Cancer Research Center at Sheba Medical Center.
It was published in the journal Oncotarget on October 22.
"In research published in 2017, we discovered a mechanism that causes the self-destruction of human cancer cells during their duplication (mitosis) without affecting normal cells," explains Prof. Cohen-Armon.
"We have now harnessed this information to efficiently eradicate human pancreatic cancer cells in xenografts. The current results were obtained using a small molecule that evokes this self-destruction mechanism in a variety of human cancer cells.
"The mice were treated with a molecule called PJ34, which is permeable in the cell membrane but affects human cancer cells exclusively. This molecule causes an anomaly during the duplication of human cancer cells, provoking their rapid cell death. Thus, cell multiplication itself resulted in cell death in the treated cancer cells."
A month after being injected with PJ34 daily for 14 days, the pancreatic cancer cells in the tumours of the treated mice experienced a relative drop of 90%.
In one mouse, the tumour completely disappeared.
"It is important to note that no adverse effects were observed, and there were no changes in the weight gain of the mice, nor in their behaviour," says Prof. Cohen-Armon.
This mechanism acts efficiently in other types of cancer resistant to current therapies.
The molecule PJ34 is being tested in pre-clinical trials according to FDA regulations before clinical trials begin.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.